Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + anlotinib for recurrent or metastatic head and neck malignant tumors
ChiCTR1800019932Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and anlotinib in head and neck cancer (HNC), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
capecitabineanlotinib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR1800019932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019932.